Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley 2022-04-01
Edice:Thoracic Cancer
Témata:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
On-line přístup:https://doi.org/10.1111/1759-7714.14357
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky